# US 2015/0104523 A1 · Therapeutic compositions and methods for addressing physiological stresses and aging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104523 A1
- Document ID: US20150104523A1
- Status: Published application
- Kind: A1
- Application number: 14/513,137
- Filed: 2014-10-13
- Published: 2015-04-16
- Earliest claimed: 2013-10-13
- Assignees: 4Life Patents, LLC
- Applicants: 4Life Patents, LLC
- Inventors: Christopher M. Lockwood
- Web page: https://patentgrep.com/patent/US20150104523A1

## CPC

- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A23L 29/00: Foods or foodstuffs containing additives (containing additives for modifying the nutritive qualities A23L33/10; containing substantially indigestive additives, e.g. dietary fibres, A23L33/21; containing additives for preservation A23B); Preparation or treatment thereof
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/12: Ketones
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 35/20: Milk; Whey; Colostrum
- A61K 35/57: Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/67: Piperaceae (Pepper family), e.g. Jamaican pepper or kava
- A61K 36/704: Polygonum, e.g. knotweed
- A61K 36/79: Schisandraceae (Schisandra family)
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.

## Claims

### Claim 1

A dietary supplement, comprising:
an immune modulator component; and
an adaptogenic nutrient component consisting of a blend of adaptogenic nutrients,
the immune modulator component and the adaptogenic nutrient component being tailored to moderate an inflammatory response by a body of a subject to a physiological stress or as a characteristic of advanced aging.

### Claim 2 (depends on 1)

The dietary supplement of claim 1, wherein the immune modulator component and the adaptogenic nutrient component are tailored to reduce the inflammatory response by the body of the subject to the physiological stress or as a characteristic of advanced aging.

### Claim 3 (depends on 1)

The dietary supplement of claim 1, wherein the immune modulator component and the adaptogenic nutrient component are tailored to moderate an amount of at least one of tumor necrosis factor-α, protein carbonyls and mitochondrial superoxide dismutase-2 in tissue of the subject.

### Claim 4 (depends on 1)

The dietary supplement of claim 1, wherein the immune modulator component and the adaptogenic nutrient component are tailored to reduce an amount of at least one of tumor necrosis factor-α and protein carbonyls in the body of the subject.

### Claim 5 (depends on 1)

The dietary supplement of claim 1, wherein the immune modulator component and the adaptogenic nutrient component are tailored to increase an amount of mitochondrial superoxide dismutase-2 in the body of the subject.

### Claim 6 (depends on 1)

The dietary supplement of claim 1, wherein the adaptogenic nutrient component consists of at least one adaptogenic nutrient selected from the group of Rhaponticum carthamoides, Schisandra chinensis, Camellia sinensis, Withania somnifera, Curcuma longa, Polygonum cusipadatum, Piper nigrum, Panax quinquefolius, Panax ginseng, Eleutherococcus senticosus, Emblica officinalis, Astragalus membranaceus, Cordyceps sinensis, Codonopsis pilosula, Tinospora cordifolia, Polygonum multiflorum, Ocimum sanctum, Gynostemma pentaphyllum, Glycyrrhiza glabra, Lycium chinense, Pseudostellaria heterophylla, Ganoderma lucidum, Rhodiola rosea, Asparagus racemosus, shilajit (Asphaltum punjabianum), Takus baccata, Pfaffia paniculata, Vitis vinifera, Silybum marianum, Bacopa monnieri, acetyl-1-carnitine, colostrum, whey, milk, and an extract of any of the foregoing.

### Claim 7 (depends on 1)

The dietary supplement of claim 1, wherein the transfer factor component is selected from the group of at least one transfer factor-containing extract and a low molecular weight fraction immune modulator-containing extract.

### Claim 8 (depends on 1)

The dietary supplement of claim 1, consisting essentially of the adaptogenic herb component and the transfer factor component.

### Claim 9 (depends on 1)

The dietary supplement of claim 1, consisting of the adaptogenic herb component and the transfer factor component.

### Claim 10

A dietary supplement, consisting essentially of:
a transfer factor-containing extract;
a low molecular weight fraction immune modulator-containing extract;
Rhaponticum carthamoides extract;
Schisandra chinensis extract;
acetyl-1-carnitine HCl;
Camellia sinensis extract;
Withania somnifera extract;
a source of a curcuminoid;
a source of resveratrol; and
a source of piperine.

### Claim 11 (depends on 10)

The dietary supplement of claim 10, formulated to moderate an inflammatory response by a body of a subject to a physiological stress or as a characteristic of advanced aging.

### Claim 12

A method for addressing an inflammatory response by a body of a subject to a physiological stress, comprising:
subjecting a body of a subject to a physiological stress that causes an increase in an inflammatory response by the body; and
within a predetermined period of time before, during or within a predetermined period of time after subjecting the body of the subject to the physiological stress, administering an immune modulator and a blend of adaptogenic nutrient components to the subject, the immune modulator and the blend of adaptogenic nutrient components moderating the inflammatory response by the body of the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein comprises subjecting the body of the subject to at least one of an inflammatory diet, strenuous work hours, vigorous exercise, sleep deprivation, extended travel, aging or an environmental pollutant.

### Claim 14 (depends on 12)

The method of claim 12, wherein administering is effected over a period of at least one month and further includes moderating a central fat mass of the body of the subject.

### Claim 15 (depends on 12)

The method of claim 12, wherein administering is effected over a period of at least one month and further includes moderating a body mass of the body of the subject.

### Claim 16 (depends on 12)

The method of claim 12, wherein administering is effected acutely.

### Claim 17 (depends on 12)

The method of claim 12, wherein:
subjecting comprises increasing an amount of at least one of tumor necrosis factor-α and protein carbonyls in the body of the subject; and
administering includes moderating an amount of at least one of the tumor necrosis factor-α and protein carbonyls in the body of the subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein moderating includes decreasing the amount of at least one of tumor necrosis factor-α and protein carbonyls in the body of the subject.

### Claim 19 (depends on 12)

The method of claim 12, wherein administering further includes administering a low molecular weight fraction immune modulator to the subject.

### Claim 20

A method for addressing an inflammatory response by a body of a subject to a physiological stress or as a characteristic of advanced aging, comprising:
subjecting a body of a subject to a physiological stress that causes a decrease in a detoxifying defense by the body; and
within a predetermined period of time before, during or within a predetermined period of time after subjecting the body of the subject to the physiological stress, administering an immune modulator and a blend of adaptogenic nutrient components to the subject, the immune modulator and the blend of adaptogenic nutrient components moderating the detoxifying defense by the body of the subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein:
subjecting comprises decreasing an amount of mitochondrial superoxide dismutase-2 in the body of the subject; and
administering comprises moderating the amount of mitochondrial superoxide dismutase-2 in the body of the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein moderating includes increasing the amount of mitochondrial superoxide dismutase-2 in the body of the subject.

### Claim 23 (depends on 20)

The method of claim 20, wherein administering further includes administering a low molecular weight fraction immune modulator to the subject.
